AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
ConvaTec Raises Full-Year Outlook as Strong Revenue Growth Boosts Confidence
November 13, 2024 03:52 AM AEDT| By Team Kalkine MediaHighlights:,●,Upgraded Guidance:,ConvaTec raises its full-year organic revenue growth forecast to 7.25-8.0% from 5-7%.,●,Improved Profit Margin:,Adjusted operating profit margin outlook increased to at least 21.5%.,●,Positive Market Reaction:,Shares...
23andMe Cuts 40% of Staff, Exits Therapeutics Amid Financial Strain
November 13, 2024 03:25 AM AEDT| By Team Kalkine MediaHighlights:,Workforce and Strategy Overhaul,: 23andMe cuts 40% of staff and halts therapeutics programs to focus on core genetics business, targeting $35 million in savings.,Data Breach and Legal Settlement,: A major breach affected 6.9 million users...
Could Polarean Imaging’s New VP Truly Drive Growth in Lung Imaging?
November 12, 2024 10:11 PM AEDT| By Team Kalkine MediaHighlights,Polarean Imaging focuses on advancements in functional lung imaging technology.,The company has set a higher revenue target, emphasizing growth in the medical imaging sector.,A new VP has introduced a strategic approach to boost Polarean's...
GSK Downgraded as Analysts Cite Limited Near-Term Growth Prospects
November 12, 2024 07:37 PM AEDT| By Team Kalkine MediaHighlights:,Jefferies Downgrades GSK:,US bank Jefferies has reduced GSK's rating to 'hold,' citing a lack of upcoming catalysts for growth.,Concerns Over Vaccine Performance:,Analysts pointed to uncertainties surrounding GSK’s Shingrix (Shingles) and...
AstraZeneca Unveils Ambitious $3.5 Billion Expansion Plan in the U.S.
November 12, 2024 07:37 PM AEDT| By Team Kalkine MediaHighlights:,Major U.S. Investment:,AstraZeneca to invest $3.5 billion in expanding its R&D and manufacturing capabilities across the U.S. by 2026.,Job Creation:,The plan includes $2 billion earmarked to generate over 1,000 high-skilled jobs in the ph...
AstraZeneca and Amgen Announce Positive Phase III Results for Tezspire in Treating Nasal Polyps
November 08, 2024 08:10 PM AEDT| By Team Kalkine MediaHighlights:,Significant Symptom Relief,:,Tezspire,(,tezepelumab,) reduced nasal polyp size and congestion in patients with chronic rhinosinusitis.,New Treatment Potential,:,The study suggests a promising alternative for patients with limited options,...
Indivior Engages with Activist Investor Oaktree Amid Calls for Board Overhaul
November 08, 2024 07:50 PM AEDT| By Team Kalkine MediaHighlights:,Oaktree Challenges Indivior Board,:,Activist investor Oaktree Capital seeks a major shake-up of Indivior’s board, citing concerns over strategy and spending.,Indivior Remains Open to Dialogue,:,The specialty pharma firm has been in active...
AstraZeneca Grapples with Market Uncertainty Following Value Decline
November 08, 2024 07:37 PM AEDT| By Team Kalkine MediaHighlights:,Significant Market Decline:,AstraZeneca has seen its market value drop by £50 billion since September, driven by concerns over its drug pipeline and China operations.,Pipeline Worries:,Disappointing trial results for the dato-DXd cancer d...
Positive Tezspire Trial Results Generate Enthusiasm at AstraZeneca
November 08, 2024 07:16 PM AEDT| By Team Kalkine MediaHighlights:,AstraZeneca announces positive results from the Phase III WAYPOINT trial for Tezspire (tezepelumab), a treatment for nasal polyps.,The trial demonstrated a statistically significant reduction in nasal polyp size and improved nasal congest...
Spire Healthcare Finalizes Strategic Share Buyback
November 08, 2024 07:01 PM AEDT| By Team Kalkine MediaHighlights:,Spire Healthcare Group PLC has completed the repurchase of 50,000 of its shares on the London Stock Exchange.,The shares were repurchased at prices ranging from 216 to 218 pence each, as part of the company’s ongoing buyback program.,The...
Roquefort Therapeutics Advances Growth Plans with Loan Note Conversion
November 07, 2024 06:25 PM AEDT| By Team Kalkine MediaHighlights:,Roquefort Therapeutics PLC converts convertible loan notes into new shares.,The move is part of the company’s strategy to expand in immunology and oncology.,New shares will be admitted to trading on the London Stock Exchange.,Roquefort Th...
AstraZeneca Pledges Cooperation with China in Ongoing Anti-Corruption Probe
November 07, 2024 08:32 AM AEDT| By Team Kalkine MediaHighlights:,Fraud Investigation Involving Executives:,AstraZeneca faces scrutiny as reports indicate involvement of senior China executives in a major pharmaceutical insurance fraud case.,Commitment to Cooperation:,AstraZeneca has pledged full cooper...
Novo Nordisk Outpaces Expectations with Wegovy Sales Surge, Raises Outlook Amid Pricing Pressures
November 07, 2024 08:25 AM AEDT| By Team Kalkine MediaHighlights:,Wegovy Sales Surge Past Forecasts:,Sales of Novo Nordisk's weight-loss drug, Wegovy, soared to $2.49 billion, surpassing analyst projections and signaling strong market demand.,Robust Group Sales Growth:,Despite a slight miss in total sal...
Spire Healthcare Advances with Strategic Share Buyback
November 06, 2024 07:21 PM AEDT| By Team Kalkine MediaHighlights:,Spire Healthcare Group executes a share repurchase, acquiring 50,000 ordinary shares.,The repurchase reduces the total number of shares in circulation to 403,988,352.,This move reflects Spire's financial strength and aims to enhance share...
Poolbeg Pharma’s POLB 001 Shows Promise in Reducing CRS Severity in Cancer Immunotherapy
November 06, 2024 06:58 PM AEDT| By Team Kalkine MediaHighlights:,Preventative Potential,:,POLB 001,demonstrated,success in reducing cytokine release syndrome (CRS) severity in preclinical models.,Clinical Accessibility,:,The drug could broaden access to cancer immunotherapies, making outpatient treatme...
Roquefort Therapeutics Advances STAT-6 siRNA Research in Immunology and Oncology
November 06, 2024 06:40 PM AEDT| By Team Kalkine MediaHighlights:,Innovative Gene-Targeting Approach,:,Roquefort’s STAT-6 siRNA,programme,targets inflammation and immune response at the genetic level.,Promising Reductions in Inflammatory Markers,:,Data show a tenfold decrease in STAT-6 protein and reduc...
AstraZeneca Loses £15bn in Value Over Weight Loss Drug Data, China Fraud News
November 06, 2024 03:47 AM AEDT| By Team Kalkine MediaHighlights:,Early Data Disappoints on Weight Loss Drug:,AstraZeneca presented preliminary data for its GLP-1 weight loss drug, which fell short of some analysts’ expectations.,China Investigation Impact:,Reports indicate several AstraZeneca China exe...
hVIVO PLC to Showcase Insights at Jefferies London Healthcare Conference
November 05, 2024 07:31 PM AEDT| By Team Kalkine MediaHighlights:,hVIVO CEO, Yamin 'Mo' Khan, will present at the Jefferies Healthcare Conference in London on 19 November 2024 at 12:00pm GMT.,The Jefferies Healthcare Conference is the largest of its kind in Europe, attracting over 650 healthcare compani...
International Biotechnology Trust Reports Strong NAV Growth and Strategic Success
November 05, 2024 06:59 PM AEDT| By Team Kalkine MediaHighlights,Strong NAV Performance,: NAV rose 15.9%, outperforming the NASDAQ Biotechnology Reference Index’s 15.3% gain.,Strategic Investment Gains,: Success in M&A and unquoted investments contributed significantly to the Trust's outperformance.,Gov...
Spire Healthcare’s Buyback of Shares Successfully Completed
November 05, 2024 06:42 PM AEDT| By Team Kalkine MediaHighlights:,Spire Healthcare has repurchased 50,000 of its ordinary shares on the London Stock Exchange.,The share repurchase forms part of the company's ongoing buyback program.,Following the transaction, Spire Healthcare’s total number of shares in...
AI on the Rise: A Look at Top AI Companies and Their Stocks